Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $35.8052W HIGH $80.97
Volume
81.27 K
Value Traded
61.36 M
Short % Float
19.05%
-4.19%Week
-10.28%1 Month
-14.19%3 Month
-4.64%6 Month
+121.55%5 Year
+121.55%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.72 B
EPS (TTM)
-2.53
P/E Ratio
-
Ent. Value
4.70 B
Total Shares
88.64 M
Float Shares
59.09 M
Insiders
33.33%
Institutions
89.36%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CGON Catalyst Timeline
Dated clinical, regulatory and corporate events for CG Oncology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for CG Oncology, Inc.
117Total events
2Upcoming
43Tier-1 (high impact)
2023 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Publicationcretostimogene grenadenorepvecPresentation
Publication of BOND-003 Cohort C results in The Lancet Oncology
high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situsource ↗
▲Primary Endpoint Metcretostimogene grenadenorepvecClinical Data
BOND-003 Cohort C met primary endpoint with statistical significance
high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situsource ↗
▲Full Resultscretostimogene grenadenorepvecClinical Data
Publication of BOND-003 Cohort C results in The Lancet Oncology
high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situsource ↗
▲PublicationcretostimogeneFiledPresentation
BOND-003 Cohort C results published in The Lancet Oncology
high-risk, BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situsource ↗
▲IP Litigation RulingIP / Competition
Delaware Superior Court denied ANI's post-trial motion, upholding jury verdict in favor of CG Oncology
◆Oral PresentationPresentation
CG Oncology at Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationPresentation
RBC Capital Markets Global Healthcare Conference fireside chat
●Oral PresentationPresentation
2025 NMIBC Research Fellowship grant recipients presented research at SUO 2026 Annual Meeting at the AUA
Non-Muscle Invasive Bladder Cancersource ↗
◆Oral PresentationcretostimogeneFiledPresentation
First results from CORE-008 Cohort CX presented at AUA 2026
HR NMIBC BCG-exposed and BCG-unresponsivesource ↗
●Oral PresentationcretostimogeneFiledPresentation
CORE-008 Cohort CX data presented at AUA 2026 Annual Meeting
HR BCG-exposed and BCG-unresponsive NMIBCsource ↗
◆Oral PresentationPresentation
CG Oncology to present at TD Cowen 46th Annual Health Care Conference
◆Topline Readoutcretostimogene grenadenorepvecClinical Data
Topline data for PIVOT-006 Phase 3 trial of cretostimogene monotherapy in intermediate-risk NMIBC expected in 1H 2026
intermediate-risk non-muscle invasive bladder cancersource ↗
▲Topline ReadoutcretostimogeneFiledClinical Data
Topline data from BOND-003 Cohort P of cretostimogene monotherapy in BCG-UR papillary-only NMIBC
BCG-unresponsive papillary-only NMIBCsource ↗
●Oral PresentationcretostimogeneFiledPresentation
Late-Breaking Abstract presentation at SUO 26th Annual Meeting
NMIBCsource ↗
▲Topline Readoutcretostimogene grenadenorepvecClinical Data
First results from CORE-008 Cohort A of cretostimogene monotherapy in BCG-naïve NMIBC with CIS
high-risk BCG-naïve NMIBC with CISsource ↗
●Oral Presentationcretostimogene grenadenorepvecPresentation
Late-Breaking Abstract presentation at SUO 26th Annual Meeting
NMIBCsource ↗
▲Oral PresentationcretostimogeneFiledPresentation
Late-Breaking Abstract at SUO 26th Annual Meeting: BOND-003 Cohort P data
HR BCG UR Ta/T1 diseasesource ↗
●BLA SubmissioncretostimogeneFiledRegulatory Filing
BLA initiation for cretostimogene
Non-Muscle Invasive Bladder Cancer (NMIBC)source ↗
●BLA SubmissioncretostimogeneFiledRegulatory Filing
Initiated rolling BLA submission for cretostimogene monotherapy
high-risk BCG-unresponsive NMIBC with CIS with or without Ta/T1 diseasesource ↗
◆BLA SubmissioncretostimogeneFiledRegulatory Filing
BLA submission for cretostimogene in HR NMIBC unresponsive to BCG
high-risk NMIBC unresponsive to BCGsource ↗
◆Timing Guidancecretostimogene grenadenorepvecPresentation
BLA submission for cretostimogene planned in Q4 2025
high-risk NMIBC unresponsive to BCGsource ↗
◆Topline ReadoutcretostimogeneFiledClinical Data
Topline data from BOND-003 Cohort P
HR BCG-unresponsive NMIBC in Ta/T1 disease without CISsource ↗
◆Oral PresentationcretostimogeneFiledPresentation
Presentation of updated BOND-003 Cohort C data at New England Section of AUA 94th annual meeting
high-risk NMIBC unresponsive to BCGsource ↗
▲Full ResultscretostimogeneFiledClinical Data
Updated 24-month CR rate of 41.8% and additional 12 patients in CR at 24 months
high-risk non-muscle invasive bladder cancer (NMIBC) unresponsive to BCGsource ↗
▲Enrollment Completecretostimogene grenadenorepvecTrial
Completed enrollment in PIVOT-006 Phase 3 trial of cretostimogene grenadenorepvec in intermediate-risk NMIBC
intermediate-risk non-muscle invasive bladder cancersource ↗
◆Oral PresentationPresentation
CG Oncology management to present at upcoming investor conferences
▲Enrollment CompletecretostimogeneFiledTrial
Enrollment completed for BOND-003 Cohort P
BCG-unresponsive papillary-only NMIBCsource ↗
▲Enrollment Completecretostimogene grenadenorepvecTrial
Enrollment completed for BOND-003 Cohort P (56 patients across 35 sites in US and Japan)
BCG-unresponsive papillary-only NMIBCsource ↗
▲Full ResultscretostimogeneFiledClinical Data
Presented 24-month CR rate of 41.8% from BOND-003 Cohort C
high-risk BCG-unresponsive NMIBC with CIS with or without Ta/T1 diseasesource ↗
▲Trial Initiationcretostimogene grenadenorepvecTrial
Initiated CORE-008 Cohort CX evaluating cretostimogene + gemcitabine
high-risk BCG-exposed NMIBCsource ↗
▲IP Litigation RulingIP / Competition
Unanimous verdict that CG Oncology owes no future royalties or payments to ANI Pharmaceuticals
▲IP Litigation Rulingcretostimogene grenadenorepvecIP / Competition
Jury verdict in favor of CG Oncology, no future royalties owed to ANI
bladder cancersource ↗
▲IP Litigation Rulingcretostimogene grenadenorepvecIP / Competition
Court ruling that ANI not entitled to future royalties on cretostimogene
bladder cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How CGON actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | Cretostimogene Grenadenorepvec | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C42 / 100
Pipeline Score
$198M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 33%
Small Cap(rank 218 of 658)
Percentile Rank
CG Oncology, Inc. carries a moderate pipeline score (42/100), with $304M risk-adjusted pipeline value, led by CG0070 in Non Muscle Invasive Bladder Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CG0070 Monoclonal antibodyCompletedNCT04387461 | Non Muscle Invasive Bladder Cancer | Phase 2 | COMPLETED | 35 | May 28, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every CGON program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| cretostimogene grenadenorepvec BreakthroughFast Track | high-risk, BCG-unresponsive non-muscle invasive bladder cancer | Phase 3 | 2026-07-27 | median duration of response: 27.9 months; complete response rate: 75.5% (95% CI 66.3 · 83.2); 12 month duration of response: 64.2% (95% CI 52.2 · 73.8); 24 month duration of response: 60.1% (95% CI 48.2 · 70.0); progression free survival 48 weeks: 96.6%; progression free survival 96 weeks: 96.6%Read More | CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet OncologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| POST LEONARD EDirector | Option | 1,000 1,000 held | $0.60 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CGON
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 5.2 % (10.6 %) | 604.96 M | 8.51 M | 21.9% ( 1.53 M) |
CGON Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CGON ranks across every disease it competes in
Competitive Position is a premium feature
See how CGON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCGON News
CGONCG Oncology to Present at Upcoming Investor Conferences in September
CG Oncology, Inc. announced that its CEO, Arthur Kuan, will present at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in September 2026. The presentations will take place on September 9 and September 14, respectively. Interested parties can access the live audio webcasts from the company's website, with replays available afterward.
Read more →CGONCG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
CG Oncology reported its second quarter 2026 financial results, highlighting significant advancements in clinical trials and a strong cash position of $1.0 billion. The company anticipates topline data from the PIVOT-006 Phase 3 trial soon and plans to complete a BLA submission for HR BCG-unresponsive NMIBC by Q4 2026. Despite an increase in net loss and R&D expenses, CG Oncology remains optimistic about its future prospects.
Read more →CGONCG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
CG Oncology has published results from the pivotal Phase 3 BOND-003 Cohort C trial in The Lancet Oncology, demonstrating the efficacy of cretostimogene grenadenorepvec for treating high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The study reported a median duration of response of 27.9 months and high rates of bladder preservation. The findings suggest that cretostimogene could significantly improve treatment options for patients facing severe interventions like cystectomy.
Read more →CGONCG Oncology to Present at Upcoming Investor Conferences in June 2026
CG Oncology, Inc. announced that its CEO, Arthur Kuan, will present at two major investor conferences in June 2026. The events include the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. These presentations aim to enhance investor engagement and showcase the company's focus on bladder cancer therapies.
Read more →CGONCG Oncology to Present at Upcoming Investor Conferences in June
CG Oncology, Inc. has announced that its CEO, Arthur Kuan, will present at two significant investor conferences in June 2026. The events include the Jefferies Global Healthcare Conference in New York and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami. These presentations aim to enhance investor engagement and showcase the company's advancements in bladder cancer therapies.
Read more →CGONSUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
CG Oncology and SUO-CTC have announced the recipients of the second annual NMIBC Research Fellowship. Dr. Patrick Hensley and Dr. Daniel Joyce each received grants of up to $50,000 to advance research in non-muscle invasive bladder cancer. Previous awardees presented their findings at the SUO 2026 Annual Meeting, showcasing significant advancements in the field.
Read more →CGONCG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
CG Oncology has reported promising results from its CORE-1008 Cohort CX Phase 2 trial, which evaluates the combination of cretostimogene grenadenorepvec and gemcitabine in patients with high-risk non-muscle invasive bladder cancer. The trial demonstrated high complete response rates and favorable event-free survival rates. The findings suggest that this combination therapy could enhance treatment options for patients who are BCG-exposed or unresponsive.
Read more →CGONCG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
CG Oncology will participate in the AUA 2026 Annual Meeting, presenting results from the CORE-008 Cohort CX Phase 2 Trial. This trial evaluates an intravesical combination therapy for patients with high-risk BCG-exposed and BCG-unresponsive non-muscle invasive bladder cancer. The company aims to advance innovative therapies and will exhibit at booth #3051.
Read more →CGONCG Oncology Reports…
CG Oncology reported its financial results for Q1 2026, highlighting a strong cash position of $1.1 billion and progress towards completing its BLA submission for HR BCG-unresponsive NMIBC by Q4 2026. The company anticipates topline data from the Phase 3 PIVOT-006 trial and results from the Phase 2 CORE-008 trial in the near future. Despite these advancements, CG Oncology reported a net loss of $60.2 million, reflecting increased R&D and G&A expenses.
Read more →CGONCG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
CG Oncology reported its Q1 2026 financial results, highlighting a strong cash position of $1.1 billion. The company is on track to complete its BLA submission for HR BCG-unresponsive NMIBC by Q4 2026. Key upcoming milestones include topline data from the Phase 3 PIVOT-006 trial and results from the Phase 2 CORE-008 trial, both expected in 2026.
Read more →CGONCG Oncology to Present…
CG Oncology, Inc. announced that its CEO Arthur Kuan and COO Ambaw Bellete will participate in fireside chats at two upcoming investor conferences: the Bank of America Health Care Conference on May 12 and the RBC Capital Markets Global Healthcare Conference on May 20. The presentations will be accessible via live audio webcast on the company's website.
Read more →CGONCG Oncology to Present at Upcoming Investor Conferences in May
CG Oncology, Inc. will present at two upcoming investor conferences in May 2026. CEO Arthur Kuan and COO Ambaw Bellete will participate in fireside chats at the Bank of America Health Care Conference on May 12 and the RBC Capital Markets Global Healthcare Conference on May 20. These events aim to enhance investor engagement and showcase the company's developments in bladder cancer therapies.
Read more →CGONCG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
CG Oncology reported its financial results for 2025 and provided updates on its clinical trials. The company anticipates topline data from the PIVOT-006 Phase 3 trial and CORE-008 Phase 2 trial in the first half of 2026. With a strong cash position, CG Oncology aims to establish cretostimogene as a leading therapy for intermediate-risk and high-risk NMIBC patients. However, the company also reported increased losses and rising expenses.
Read more →CGONCG Oncology to Present at the TD Cowen 46th Annual Health Care Conference
CG Oncology, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CEO Arthur Kuan and COO Ambaw Bellete will lead the presentation, which can be accessed via a live audio webcast. The company aims to develop innovative therapies for bladder cancer patients.
Read more →CGON▲ +29.3%on this news
CG Oncology Provides…
CG Oncology has announced an expedited timeline for the topline data readout of the PIVOT-006 Phase 3 clinical trial, now expected in the first half of 2026. This trial evaluates the efficacy of cretostimogene grenadenorepvec in patients with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC). The trial is notable for being the first randomized registrational study in this patient population, aiming to address a significant unmet medical need.
Read more →CGON▲ +29.3%on this newsshared move
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
CG Oncology has announced an expedited timeline for topline data from the PIVOT-006 Phase 3 trial, now expected in the first half of 2026. This trial evaluates cretostimogene for intermediate-risk non-muscle invasive bladder cancer (NMIBC) and is the first randomized study in this patient group. The rapid enrollment across over 90 sites highlights the urgent need for treatment options in this area.
Read more →CGONCG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
CG Oncology, a late-stage clinical biopharmaceutical company, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be led by CEO Arthur Kuan and COO Ambaw Bellete. Interested parties can access the live audio webcast through the company's website.
Read more →CGONSUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
CG Oncology and SUO-CTC have announced the second annual NMIBC Research Fellowship, offering two grants of $50,000 each. This initiative aims to foster clinical cancer research focused on Non-Muscle Invasive Bladder Cancer (NMIBC). Applications are due by February 27, 2026, and selected projects will be presented at the AUA annual meeting.
Read more →CGONNew Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
CG Oncology announced positive topline data from BOND-003 Cohort P and CORE-008 Cohort A, indicating that cretostimogene may serve as a backbone therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The results show high-grade event-free survival rates and a favorable safety profile, with no serious adverse events reported. These findings will be presented at the Society of Urologic Oncology's annual meeting.
Read more →About CG Oncology, Inc.
Headquarters3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
BIOPHARMAWATCH ELITE PLUS
Trade the next CGON catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime